PATENT CLAIM ANALYSIS

Application Number: 16020688
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "267000"]

Abstract:
The present invention provides, inter alia, compounds capable of inhibiting NF-κB. Pharmaceutical compositions containing and methods of using the compounds are also provided herein. Also provided are methods and kits for treating cancer and solid tumors in a subject, as well as methods and kits for inducing cancer cell death and apoptosis of a cancer cell, all utilizing the NF-κB inhibitors described herein.

Claim (Index 4):
The method according to  claim 3 ,\n wherein:\n Z is oxygen; \n R 1  and R 3  are selected from the group consisting of hydrogen, halogen, \u2014CN, and \u2014CF 3 ; \n R 2  is selected from the group consisting of C 1-9  alkoxy, \u2014OC n H 2n OMe, \u2014OC n H 2n OC m H 2m OMe, \u2014OC n H 2n OH, \u2014OC n H 2n OC m H 2m OH, OC n H 2n OEt, \u2014OC n H 2n OC m H 2m OEt, \u2014O\u2014C n H 2n COOH, \u2014O\u2014C n H 2n CONH2, \u2014O\u2014C n H 2n CONHMe, and \u2014OH; \n m is 2, 3, 4 or 5; \n n is 2, 3, 4, or 5; and \n R 4  is selected from the group consisting of hydrogen, C 1-9  alkoxy and \u2014OH, \n or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 94.0
- Lexical Diversity: 1.59091
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15393507', '12604970', '14032739', '13035640', '14088804']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8110713844744992
- 35 USC 102 Novelty (BERT): 0.5700607331742085
- Combined Prediction Score: 0.7869703193444701
- Mean Citation Score: 335.78576400000014
- Max Citation Score: 451.7303
- Similarity Product: 428.15150433245896

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test